PT - JOURNAL ARTICLE AU - de Mello Malta, Fernanda AU - Amgarten, Deyvid AU - Val, Felipe Camilo AU - Santana, Rubia Anita Ferraz AU - Cervato, Murilo Castro AU - de Azevedo, Bruna Mascaro Cordeiro AU - de Souza Basqueira, Marcela AU - Alves, Camila Oliveira dos Santos AU - Nobrega, Maria Soares AU - Pinho, João Renato Rebello TI - Mass molecular testing for COVID19 using NGS-based technology and a highly scalable workflow AID - 10.1101/2020.08.10.20172106 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.10.20172106 4099 - http://medrxiv.org/content/early/2020/08/11/2020.08.10.20172106.short 4100 - http://medrxiv.org/content/early/2020/08/11/2020.08.10.20172106.full AB - Since first reported case of the new coronavirus infection in Wuhan, China, researchers and governments have witnessed an unseen rise in the number of cases. Thanks to the rapid work of Chinese scientists, the pathogen now called SARS-CoV-2 has been identified and its whole genome has been deposited in public databases by early January 2020. The availability of the genome has allowed researchers to develop Reverse Transcription - Polymerase Chain Reaction (RT-PCR) assays, which are now the gold-standard for molecular diagnosis of the respiratory syndrome COVID19. Because of the rising number of cases and rapid spreading, the world has been facing a shortage of RT-PCR supplies, especially the ones involved in RNA extraction. This has been a major bottleneck to increase testing capacity in many countries that do not significantly manufacture these supplies (Brazil included). Additionally, RT-PCR scalability is highly dependent on equipment that usually perform testing of 96 samples at a time. In this work, we describe a cost-effective molecular NGS-based test for diagnosis of COVID19, which uses a single-step RNA extraction and presents high scalability and accuracy when compared to the gold-standard RT-PCR. A single run of the NGS-based test using the Illumina NextSeq 550 mid-end sequencing equipment is able to multiplex 1,536 patient’s samples, providing individual semi-qualitative results (detected, not detected). Detected results are provided with fragments per million (FPM) values, which was demonstrated to correlate with RT-PCR Cycle Threshold (CT) values. Besides, usage of the high-end Illumina Novaseq platform may yield diagnostic for up to 6,144 samples in a single run. Performance results when compared with RT-PCR show general accuracy of 96% (or 98% when only samples with CT values for gene N lower than 30 are considered). We have also developed an online platform, called VarsVID®, a Varstation® feature, to help test executors to easily scale testing numbers. Sample registering, wet-lab worksheets, sample sheet for sequencing and results’ display are all features provided by VarsVID® on Varstation®. Altogether, these results will contribute to control COVID19 pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical samples presented in this work were used according to approval of the Hospital Israelita Albert Einstein Ethical Committee under report #4.178.076.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNGS data, as well as sample sheets and results are available under request.